

Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers

Abdulafeez Akinloye¹; Timothy Oyediji¹; Oluwasegun Eniyewu^{1,2}; Babatunde Adeagbo¹; Oluseye Bolaji¹; Steve Rannard³; Andrew Owen⁴; Adeniyi Olagunju⁴

¹Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria;

²Department of Pharmaceutical and Medicinal Chemistry, University of Ilorin, Ilorin, Nigeria;

³Department of Chemistry, University of Liverpool, Liverpool, United Kingdom.

⁴Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Correspondence: Dr Adeniyi Olagunju. Department of Pharmacology and Therapeutics, Sherrington Building, Ashton Street, University of Liverpool, Liverpool, L69 3GE, United Kingdom. Tel.: +44 (0)151 794 40418. Email: olagunju@liverpool.ac.uk.

Authors' contributions: Abdulafeez Akinloye: Bioanalysis, data analysis and writing – original draft; Timothy Oyediji: Bioanalysis and writing – original draft; Oluwasegun Eniyewu: Bioanalysis, data analysis and writing – original draft; Babatunde Adeagbo: Protocol design, supervision, data analysis and writing –editing and review; Oluseye Bolaji: Supervision and writing – review and editing; Steve Rannard: Supervision and writing – review and editing; Andrew Owen: Supervision and writing – review and editing; Adeniyi Olagunju: Conceptualization, protocol design, supervision, data analysis and writing – review and editing.

ABSTRACT

Aims: Nitazoxanide is a broad-spectrum antiviral with potential application in a number of viral infections. Its use is limited by gastrointestinal side effects associated with increasing dose. In this study, we investigated the possibility of enhancing the exposure of its active metabolite, tizoxanide, through pharmacokinetic interaction with atazanavir/ritonavir.

Method: This was a crossover drug-drug interaction study, 18 healthy participants received a single dose of 1000 mg of nitazoxanide alone in period 1 and in combination with 300/100 mg atazanavir/ritonavir in period 2 after a washout period of 21 days. On both days, blood samples for intensive pharmacokinetic analyses were collected before and at 0.25, 0.5, 1, 2, 4, 6, and 12 h after dose. To explore the utility of dried blood spots (DBS) as alternative to plasma for tizoxanide quantification, 50 μ L of blood from some participants was spotted on DBS cards. Pharmacokinetic parameters were derived by non-compartmental analysis and compared between periods 1 and 2. The correlation between tizoxanide concentration in plasma and DBS was also evaluated.

Results: Co-administration of nitazoxanide with atazanavir/ritonavir resulted in a significant increase in tizoxanide plasma exposure. The geometric mean ratios (90% CI) of tizoxanide AUC_{0-12h} , C_{max} and C_{12h} were 1.872 (1.870 – 1.875), 2.029 (1.99 – 2.07) and 3.14 (2.268 – 4.352) respectively, were all outside the 0.8 – 1.25 interval, implying clinically significant interaction. DBS concentration (%CV) was 46.3% (5.6%) lower than plasma concentrations, with a strong correlation ($R = 0.89$, $P < 0.001$). Similarly, DBS-derived plasma concentration and plasma concentrations displayed very strong correlation with linearity ($R = 0.95$, $P < 0.001$).

Conclusion: Co-administration with atazanavir/ritonavir enhanced tizoxanide exposure with no report of adverse events in healthy volunteers.

Keywords: Nitazoxanide; tizoxanide; atazanavir/ritonavir; drug-drug interaction; dried blood spot

1 INTRODUCTION

2 Nitazoxanide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl) benzamide, is a thiazolide anti-infective agent initially
3 developed for the treatment of veterinary helminthics [1, 2]. It has been studied for its anti-infective
4 and more recently antineoplastic properties as well as activity on bone resorption [3-5]. It possesses a
5 broad spectrum antimicrobial activity against a wide range of human pathogens, including human
6 helminthics, anaerobic bacteria, and protozoans [6-8]. Nitazoxanide has been reported to have excellent
7 activity against a few non-protozoan parasites such as the intestinal tapeworms *Hymenolepis nana* and
8 *Trichuris trichiura* as well as against viruses, including enteric, human immunodeficiency virus, the
9 Middle East respiratory syndrome, viral hepatitis, the rotaviruses and ebola virus [9-13]. Nitazoxanide is
10 rapidly metabolism to its active metabolite tizoxanide which is highly bound to plasma proteins, and the
11 inactive tizoxanide-glucuronide [14]. Recently, it was reported to possess *in-vitro* antiviral activity
12 against SARS-CoV-2 and was investigated in several drug repurposing trials for COVID-19 management
13 [15, 16].

14 However, efficacy against a new pathogen often requires systemic exposure levels that are not
15 achievable at the approved dose [17]. In addition to the time lost to getting a new dose approved in a
16 disease outbreak, tolerability may be compromised with higher doses. This has been reported for
17 nitazoxanide whose clinical use is limited by severe gastrointestinal adverse events. These adverse
18 events have been reported to be associated with increasing doses of nitazoxanide higher than 1000 mg
19 that are capable of disrupting patients' activities [18-20]. As a result, the recommended and currently
20 approved dose is 500 mg twice daily but 1000 mg has been used in previous studies with higher
21 tolerability [21].

22 Precedent exists for concomitant administration of a drug with another agent that inhibits or induces
23 certain aspect(s) of its disposition pathway to improve systemic exposure, a strategy known as
24 pharmacokinetic boosting. This has been applied to drugs used in the treatment of different disease
25 such as HIV and cancer [22-26]. Interaction between nitazoxanide and atazanavir/ritonavir has not been
26 reported. However, since viral protease inhibitors inhibit uridine 5'-diphospho-glucuronosyltransferase
27 (UDP-glucuronosyltransferase, UGT) enzymes [27], atazanavir/ritonavir is expected to inhibit the
28 glucuronidation of tizoxanide, potentially increasing its exposure. We conducted a single-dose study in
29 healthy volunteers to explore this concept.

30

31 **METHODS**

32 **Study Design and Participants**

33 This was a single centre, open-label, two-period crossover study, with a 3-week washout period in
34 between. In period 1, participants received a single dose of 1000 mg of nitazoxanide alone (two 500 mg
35 tablets) in the morning after a regular local meal. Following a 3-week washout period, participants
36 received a single dose of 1000 mg of nitazoxanide (two 500 mg tablets) along with a single dose of 300
37 mg/100 mg atazanavir/ritonavir (co-formulated tablet) in period 2. That is nitazoxanide plus
38 atazanavir/ritonavir in the morning. The study protocol was reviewed by the Institute of Public Health,
39 Obafemi Awolowo University Ile-Ife, Nigeria and approved on 16 December 2020 (IPH/OAU/12/1574).
40 The study is registered on ClinicalTrials.gov (NCT05680792). Participants were recruited from the
41 community of Obafemi Awolowo University Ile-Ife, and included healthy individuals who were at least
42 18 years old, able to understand the study information, non-smokers, and non-alcoholics. Individuals
43 who were pregnant, breastfeeding, have taken any medication or coffee within 2 weeks of their
44 participation, or allergic to nitazoxanide, atazanavir, or ritonavir were excluded. Only participants who
45 agreed to participate after understanding the study procedure and who signed the informed consent
46 form were enrolment.

47 **Sample Collection**

48 Intensive pharmacokinetic sampling was conducted after an observed single dose in each of the two
49 periods, consisting of collection of 2 mL venous blood into EDTA tubes at 0, 0.25, 0.5, 1, 2, 4, 6, and 12 h
50 after dose. Plasma was separated by immediate centrifugation at 3000 rpm for 5 min at 4°C. Plasma
51 samples were transferred into cryovials and stored at -70°C until analysis. To evaluate the potential
52 utility of the dried blood spot (DBS) method and for its cross-validation against the plasma method,
53 intensive pharmacokinetic DBS samples were collected from six individuals in period 1 and six individuals
54 in period 2. Briefly, before plasma separation from venous blood from each time point as described
55 above, 50 µL per spot was spotted within the marked circles of Whatman 903® Protein Saver card (GE
56 Healthcare Life Sciences, New York, USA). The cards were allowed to dry at room temperature for 2 h
57 before being packed into zip-lock bags containing desiccants and stored at -70°C until analysis. Both
58 plasma and DBS samples were analysed within one week of collection.

59

60 **Bioanalysis of Study Samples**

61 Quantification of tizoxanide in plasma and DBS was carried out using an earlier reported LC-MS/MS
62 method [28], modified and partially validated as follows. The LC system consisted of Accela Open
63 Autosampler and an Accela LC-Pump (Thermo Fischer Scientific, Hemel Hempstead, UK).
64 Chromatographic separation was carried out on a reverse phase Fortis™ C₁₈ column (3 μm particle size,
65 100 mm x 2.1 mm; Fortis Technologies Ltd, Neston, Cheshire, UK) with a 2 μm C₁₈ Quest guard-column
66 (Thermo Electron Corporation, Hemel Hempstead, Hertfordshire, UK). Gradient elution consisted of 10
67 mM ammonium formate in acetonitrile (mobile phase A) and 10 mM ammonium formate in water
68 (mobile phase B) at a flow rate of 400 μL/min. The gradient program started with 5% of mobile phase A,
69 maintained for 1 minute, and increased to 80% at 1.5 min. It was further increased to 95% at 4 min and
70 returned to 5% at 6 min. The total run time was 6 min. Detection was on the TSQ Vantage (Thermo
71 Electron Corporation, Hemel Hempstead, Hertfordshire, UK) with a heated electrospray 3ptimizati
72 source operated in the negative 3ptimizati mode and selective reaction monitoring. Xcalibur™ was used
73 for compound tuning and 3ptimization while the Lcquan™ (version 2.7.0, Thermo Fisher Scientific,
74 Hemel Hempstead, UK) was used for sequence acquisition and data processing.

75 Calibration standards for tizoxanide plasma and DBS assay consisted of zero blank and 9 calibrator levels
76 ranging from 50 to 20000 ng/mL, prepared by serial dilution of plasma working stock of tizoxanide with
77 drug-free plasma from a healthy volunteer. Quality control (QC) samples included a lower limit of
78 quantitation (LLOQ; 50 ng/mL), low-QC (LQC; 120 ng/mL), medium-QC (MQC; 8600 ng/mL) and high-QC
79 (HQC; 18000 ng/mL), similarly prepared from a different working stock. All working stock solutions and
80 plasma working stock were prepared from a 1 mg/mL stock solution prepared from tizoxanide reference
81 compound (Toronto Research Chemicals Inc., Toronto, ON, Canada). Efavirenz (Selleck Chemicals LLC,
82 Houston, USA) was used as internal standard.

83 Extraction of tizoxanide from the validation samples and study samples was carried out by the protein
84 precipitation method using acetonitrile. Briefly, 100 μL of plasma was transferred into clean 7 mL
85 extraction tubes, followed by the addition of 20 μL of internal standard (efavirenz; 750 ng/mL) and 20 μL
86 of formic acid. 1000 μL of acetonitrile was then added and vortexed for 10 s to precipitate proteins. The
87 extract was left to stand for 10 min and vortexed again for 10 s before centrifugation at 3500 rpm for 10
88 min at 4°C. 400 μL of the supernatant was transferred into 400 μL glass autosampler vials and the
89 injection volume was 25 μL. For DBS, three 6 mm punches were taken from a spot per sample and
90 transferred into 7 mL extraction tubes with screw caps. 500 μL of acetonitrile and 20 μL of internal
91 standard (efavirenz; 750 ng/mL) were added and vortexed for 10 s. The tubes were left to stand for 30

92 min, and vortexed for 10 s every 10 min. The extracts were centrifuged at 4000 rpm for 15 min at 4°C
93 and 400 µL of the supernatants were transferred into another clean 7 mL extraction tube. 20 µL of
94 formic acid was added to the supernatant and the samples were vortexed again. 400 µL of the final
95 extract was transferred into 400 µL glass autosampler vials and 25 µL was injected. At least 3 validation
96 assay batches for precision and accuracy were run for each sample type, and additional assay batches
97 for selectivity, recovery, matrix effect, and extraction efficiency.

98 Plasma and DBS samples obtained from the study participants were analysed in the same way as
99 described above.

100

101 **Data Analysis**

102 Bioanalytical method validation data were processed using Excel® (Microsoft Inc., Washington, USA) and
103 assessed using FDA guidance [29], including %CV within ±15% for QCs (±20% for LLOQ) in the case of
104 accuracy and precision assays. Tizoxanide pharmacokinetic parameters (AUC_{0-12h} , C_{max} , C_{12} and t_{max}) from
105 the concentration-time data for both periods were obtained by non-compartmental analysis using
106 GraphPad Prism® (GraphPad Software, La Jolla, CA). In line with the FDA guidance, geometric mean
107 ratios and their 90% CIs were calculated for AUC_{0-12} , C_{max} , and C_{12} to assess the clinical significance of any
108 observed interaction [30]. For the cross validation of the plasma and DBS methods, linear regression was
109 first used to describe the relationship between measured plasma and DBS concentrations. DBS-derived
110 plasma concentrations were calculated from the equation $DBS\text{-derived plasma} = [DBS_{conc}/(1 -$
111 $hct)] \times 0.999$ [31], where DBS_{conc} is the concentration measured in DBS, hct is average hematocrit [32] and
112 0.999 [14, 33] is the plasma bound fraction of tizoxanide. Afterwards, DBS-derived plasma
113 concentrations were compared with the paired plasma concentration using linear regression analysis.

114

115 **RESULTS**

116 **Participant's disposition and demographics**

117 A total of 25 participants consented to participate in the study but 4 withdrew from the study due to
118 illnesses, non-related to the study, such as malaria while 3 were withdrawn due to non-compliance with
119 the study protocol. Eventually, 18 participants (males, n = 10 and females, n = 8) completed the study.
120 The mean (±SD) age and mean weight (±SD) were 27.4 (6.9) years and 60.4 (12.8) kg, respectively. In
121 both periods of the study, no participant reported any serious symptom or adverse effect.

122

123 **Method Validation**

124 **Linearity, accuracy, and precision of plasma and DBS assay**

125 Linearity of the assay method for both plasma and DBS was established in more than 8 assays over the
126 range of 50 – 20000 ng/mL, with all the calibration standards having a percentage bias falling below
127 $\pm 15\%$. A typical regression coefficient (r^2) was 0.9971. For plasma assay, accuracy and precision were
128 84.4 – 112.2% and 1.0 – 0.6%; while for DBS, they were 91.8 – 108.4% and 0.49 – 13.1% (Supplementary
129 S1). All values were within the acceptance criteria from FDA guideline.

130

131 **Recovery, matrix effect, and extraction proficiency**

132 The mean (%CV) recoveries of tizoxanide from plasma at LLOQ, LQC, MQC, and HQC were 88.8% (4.6),
133 87.1% (3.8), 110.1% (7.6) and 100.9 (2.3), respectively, and the overall mean (%CV) recovery was 96.7%
134 (11.2). The plasma matrix effect was between 103.1% and 112.7% with a %CV less than ± 15 . Also, mean
135 extraction proficiency was 104.4 with %CV less than 15% for all QC levels.

136

137 **Pharmacokinetics of tizoxanide and the effects of co-administration of atazanavir/ritonavir**

138 In period 1 (nitazoxanide alone) and period 2 (nitazoxanide plus atazanavir/ritonavir), tizoxanide was
139 undetectable in the plasma until after 30 min following drug administration, and the median (range) t_{max}
140 was consistently at 4 (2 – 6) hrs (Figure 1). Geometric mean tizoxanide AUC_{0-12h} was 124967.7 ng.h/mL in
141 period 1 compared with 233984.1 ng.h/mL in period 2, representing GMR of 1.872 (Table 1). C_{max} was
142 4375.7 ng/mL for period 1 compared with 8882.1 ng/mL for period 2 (GMR: 2.029), while C_{12} was 553.8
143 ng/mL period 1 compared with 1740.7 ng/mL for period 2 (GMR: 3.143). The values obtained for the
144 parameters were outside the 0.80-1.25 range indicating clinical significance. Similarly, PK parameters
145 obtained from DBS-derived plasma concentrations showed increased exposure from period 1 to period
146 2, but the folds increase were more than what were observed in plasma (Supplementary S2 and S3).

147

148 **Plasma-DBS Cross-validation**

149 Significant correlation was observed between nitazoxanide concentration in plasma and DBS
150 correlation (coefficient, $R = 0.87$, $P < 0.001$) (Figure 2). The equation $y = 2.1343x + 53.489$ described the
151 relationship between tizoxanide concentration in the two matrices, where y is the plasma
152 concentrations and x is the DBS concentrations. Similarly, DBS-derived plasma concentrations obtained
153 from DBS concentrations had a very strong correlation with measured plasma concentration with a
154 correlation coefficient $R = 0.95$, $P < 0.001$. (Figure 3).

155

156 DISCUSSIONS

157 The pharmacokinetic interaction between oral nitazoxanide (1000 mg) and atazanavir/ritonavir
158 (300/100 mg) was successfully investigated in this single dose, cross-over study in healthy volunteers.
159 Co-administration with atazanavir/ritonavir boosted the plasma pharmacokinetics of tizoxanide, the
160 active metabolite of nitazoxanide, by 69.05%. This strategy could potentially create opportunities to
161 explore nitazoxanide for indications requiring exposure levels not achievable with the standard dose,
162 with further benefit of synergistic antiviral activity of atazanavir/ritonavir in the case of viral infections.

163 Doses higher than 500 mg of nitazoxanide were predicted to achieve tizoxanide plasma and lung tissue
164 levels to ensure EC_{90} of 1.43 mg/L required for SARS-CoV-2 viral suppression [17]. Since efficacy, ease of
165 administration and more importantly safety concerns usually inform the choice of drugs and dosing in
166 repurposed drugs [34, 35], we decided to investigate the appropriateness of a 1000 mg twice daily
167 regime since its safety has been previously established and not associated with most gastrointestinal
168 side effects associated with higher doses [36, 37]. Although this dose was reported to only achieve
169 plasma concentration higher than the EC_{90} and not in the lungs, the strategy investigated here resulted
170 in the *in situ* elevation of tizoxanide metabolite, preventing its conversion to tizoxanide-glucuronide by
171 UGT enzymes, in the presence of atazanavir, a known UGT enzyme inhibitor [27]. Additionally,
172 atazanavir/ritonavir is an antiviral drug with activity against several viral pathogens; it is reportedly
173 active *in vitro* against SARS-CoV-2 [19, 38, 39]. Hence, its combination with nitazoxanide could be
174 investigated for efficacy against SARS-CoV-2 infection and other viruses in the future. Furthermore, this
175 combination was not associated with any serious adverse events in this cohort.

176 Though atazanavir is a known inhibitor of UGT enzymes, investigating the exact mechanism was beyond
177 the scope of this study. However, pharmacokinetic boosting by intentional modulation of drug
178 disposition is not new and it is extensively used in HIV treatment (e.g. lopinavir/ritonavir,
179 atazanavir/cobisistat, elvitegravir/ cobisistat). A recent review is also available on pharmacokinetic
180 boosting strategies for kinase inhibitors [24].

181 Our exploration of the DBS method as an alternative for the plasma method was prompted by sample
182 collection limitations associated with risk mitigation strategies in pandemic settings. Samples collected
183 on DBS cards are considered non-infectious and are exempted from UN3373 transport of dangerous
184 goods regulation [40]. Hence, it could facilitate pharmacokinetic sampling as part of drug repurposing
185 trial under stringent risk mitigation strategies. The strong correlation observed between tizoxanide

186 concentration in plasma and DBS, along with good linearity in linear regression analysis allowed
187 reasonable confidence in predicting plasma concentrations from DBS concentrations using the linear
188 equation generated. The strong correlation between plasma concentration and DBS-derived plasma
189 concentration indicated the strong potential of replacing the plasma sampling method of the drug with
190 the DBS sampling approach. Advantages include ease of sample collection, no need for centrifugation,
191 storage at room temperature for stable analytes, and no need for specialized shipment beyond three-
192 component packaging. However, more studies are required to establish room temperature stability,
193 and the impact of other variables not evaluated in the present study on DBS concentration (e.g.
194 hematocrit, and plasma protein binding), in the same way these have been evaluated for some drugs,
195 such as efavirenz and dolutegravir, in the past [41, 42].

196

197 **Funding statement:** This work was supported by Obafemi Awolowo University, Nigeria and the
198 University of Liverpool, United Kingdom. No external support was received.

199 **Conflict of interest:** The authors declare no conflict of interest.

200 **Data availability statement:** The data supporting the findings of this study are available upon a request
201 to the corresponding author. No part of the data, apart from the supplementary data, is made publicly
202 available.

References

1. Abd El-Fadeal, N.M., et al., *Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/ β -Catenin Signaling Inhibition*. Int J Mol Sci, 2021. **22**(10).
2. Bolia, R., *Nitazoxanide: Jack of All, Master of None?* The Indian Journal of Pediatrics, 2020. **87**(1): p. 4-5.
3. Di Santo, N. and J. Ehrisman, *A functional perspective of nitazoxanide as a potential anticancer drug*. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014. **768**: p. 16-21.
4. Lü, Z., et al., *Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors*. ACS Med Chem Lett, 2021. **12**(5): p. 696-703.
5. Grayson, M.L., et al., *Foreword to the 6th Edition*. 2017, Taylor & Francis Group: United Kingdom.
6. Dubreuil, L., et al., *In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms*. Antimicrob Agents Chemother, 1996. **40**(10): p. 2266-70.
7. Anderson, V.R. and M.P. Curran, *Nitazoxanide: a review of its use in the treatment of gastrointestinal infections*. Drugs, 2007. **67**(13): p. 1947-67.
8. Aslam, S. and D.M. Musher, *Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent*. Future Microbiol, 2007. **2**(6): p. 583-90.
9. Chero, J.C., et al., *Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions*. Trans R Soc Trop Med Hyg, 2007. **101**(2): p. 203-5.
10. Speich, B., et al., *Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial*. PLoS Negl Trop Dis, 2012. **6**(6): p. e1685.
11. Lokhande, A.S. and P.V. Devarajan, *A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19*. Eur J Pharmacol, 2021. **891**: p. 173748.
12. Jasenosky, L.D., et al., *The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus*. iScience, 2019. **19**: p. 1279-1290.
13. Hargest, V., et al., *Astrovirus Replication Is Inhibited by Nitazoxanide In Vitro and In Vivo*. J Virol, 2020. **94**(5).
14. ZHAO, Z., et al., *The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro*. Journal of Veterinary Pharmacology and Therapeutics, 2010. **33**(2): p. 147-153.
15. Stachulski, A.V., et al., *Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus*. Future Medicinal Chemistry, 2018. **10**(8): p. 851-862.
16. Wang, M., et al., *Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro*. Cell Res, 2020. **30**(3): p. 269-271.
17. Rajoli, R.K.R., et al., *Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis*. British Journal of Clinical Pharmacology, 2021. **87**(4): p. 2078-2088.
18. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses*. Int J Clin Pharmacol Ther, 2002. **40**(5): p. 213-20.
19. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d*. Int J Clin Pharmacol Ther, 2002. **40**(5): p. 221-7.
20. Walker, L.E., et al., *An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2*. Clin Pharmacol Ther, 2022. **111**(3): p. 585-594.

21. Walsh, K.F., et al., *Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis*. Antimicrobial Agents and Chemotherapy, 2020. **64**(5): p. 10.1128/aac.01956-19.
 22. Salama, E., et al., *Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy*. J Clin Pharmacol, 2020. **60**(12): p. 1537-1550.
 23. Larson, K.B., et al., *Pharmacokinetic enhancers in HIV therapeutics*. Clin Pharmacokinet, 2014. **53**(10): p. 865-72.
 24. Westra, N., et al., *Pharmacokinetic Boosting of Kinase Inhibitors*. Pharmaceutics, 2023. **15**(4).
 25. van Veelen, A., et al., *Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial*. Lung Cancer, 2022. **171**: p. 97-102.
 26. Boosman, R.J., et al., *Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib*. Pharm Res, 2022. **39**(4): p. 669-676.
 27. Zhang, D., et al., *In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation*. Drug Metab Dispos, 2005. **33**(11): p. 1729-39.
 28. Neary, M., et al., *Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research*. J Chromatogr B Analyt Technol Biomed Life Sci, 2023. **1228**: p. 123823.
 29. FDA, *Bioanalytical Method Validation; Guidance for Industry; Availability*. 2018, Federal Information & News Dispatch, LLC: Washington. p. 23690.
 30. FDA, *Federal Notice: Clinical Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions and In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions*, in *Targeted News Service*. 2020, Targeted News Service: Washington, D.C.
 31. Li, W. and F.L.S. Tse, *Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules*. Biomedical Chromatography, 2010. **24**(1): p. 49-65.
 32. Mondal, H. and S. Lotfollahzadeh, *Hematocrit*, in *StatPearls*. 2023, StatPearls Publishing
- Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL).
33. Vets, E., J.-F. Rossignol, and A.S. Jackson, *Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin*. American Journal of Health-System Pharmacy, 2009. **66**(9): p. 838-842.
 34. Low, Z.Y., I.A. Farouk, and S.K. Lal, *Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak*. Viruses, 2020. **12**(9).
 35. Stachulski, A.V., et al., *Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?* ACS Infect Dis, 2021. **7**(6): p. 1317-1331.
 36. Blum, V.F., et al., *Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial*. EClinicalMedicine, 2021. **37**: p. 100981.
 37. Bobrowski, T., et al., *Synergistic and Antagonistic Drug Combinations against SARS-CoV-2*. Mol Ther, 2021. **29**(2): p. 873-885.
 38. Fintelman-Rodrigues, N., et al., *Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production*. Antimicrob Agents Chemother, 2020. **64**(10).
 39. Chaves, O.A., et al., *Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M(pro), Impairing Variants Replication In Vitro and In Vivo*. Pharmaceutics (Basel), 2021. **15**(1).
 40. Organization, W.H., *Guidance on regulations for the transport of infectious substances 2013-2014: applicable as from 1 January 2013*. 2012, World Health Organization.
 41. Olagunju, A., et al., *Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots*. J Antimicrob Chemother, 2015. **70**(10): p. 2816-22.

42. Akinloye, A., et al., *Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots*. *Ther Drug Monit*, 2022. **44**(3): p. 430-437.




Figure 1: Plasma concentration-time curve of tizoxanide alone and with atazanavir/ritonavir (ATZ/r); data is presented here as mean (95% CI) for

n

=18




Figure 2: Linearity between tizoxanide plasma concentrations DBS concentrations




Figure 3: Linearity between tizoxanide plasma concentrations DBS concentrations (broken line represents true line of identity)

Table 1: Pharmacokinetic parameters of plasma tizoxanide with and without atazanavir/ritonavir

Pharmacokinetic parameters (n = 18)	NTZ alone		NTZ plus ATZ/r		GMR (90% CI)
	Mean (%CV)	GM (%CV)	Mean (%CV)	GM (%CV)	
AUC _{0-12h} (ng.h/mL)	171135.9 (111.4)	124967.7 (6.4)	289297.9 (58.9)	233984.1 (6.1)	1.872 (1.870 – 1.875)
C _{max} (ng/mL)	5304.4 (64.1)	4375.7 (7.8)	10495.4 (47.7)	8882.1 (7.8)	2.029 (1.990 – 2.070)
C _τ (ng/m L)	1898.2 (262.2)	553.8 (22.9)	3082.8 (74.7)	1740.7 (29.8)	3.143 (2.268 – 4.352)

NTZ: Nitazoxanide; ATZ/r: Atazanavir/ritonavir; GM: Geometric mean; GMR: Geometric mean ratio (GM of NTZ plus ATZr/GM of NTZ alone)

